The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Lobucavir is a promising new drug with activity against cytomegalovirus in vitro and good bioavailability in animals. A single-dose study in humans showed that it was as safe as placebo, and oral bioavailability was about 40%, with saturable absorption at high doses. The current study was conducted to determine the safety and kinetics of twice-daily doses of lobucavir in clinically stable subjects...
Combination antiretroviral therapy may produce a greater immunologic and antiviral effect than monotherapy in the treatment of HIV infection. This trial is the first study of the long-term safety and antiviral activity of didanosine (Videx ) and stavudine (Zerit ) combination therapy in the treatment of HIV infection. A total of 75 subjects (15 per dose group) with previously-untreated HIV infection...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.